Table 1 Demographic and clinical characteristics at t0 (at starting omalizumab) (N = 143)
From: Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Characteristic | All patients (n:143)a |
|---|---|
Age, median (IQR) | 44 (24–57) |
Sex, female, n (%) | 96 (66.6) |
Body Mass Index, median (IQR) | 25.52 (24.36–27.47) |
Type of health insurance affiliation, n (%) | |
Contributory | 125 (87.4) |
Special regimen | 12 (8.4) |
Subsidized | 5 (3.5) |
Other | 1 (0.7) |
Cities and sites, n (%) | |
Bogotá, 2 sites | 89 (62.2) |
Bucaramanga, 1 site | 25 (17.5) |
Pereira, 1 site | 10 (7) |
Medellín, 2 sites | 10 (7) |
Cali, 1 site | 5 (3.5) |
Barranquilla, 1 site | 4 (2.8) |
Comorbidities, n (%) | |
Rhinitis | 91 (64.1) |
Sinusitis | 27 (18.9) |
Nasal polyposis | 24 (16.9) |
Gastroesophageal reflux | 15 (10.6) |
Other comorbidities | 90 (63.4) |
Eosinophils blood count, n (%) | |
< 300 cells/μL | 41 (51.9) |
≥ 300 cells/μL | 38 (48.1) |
IgE, serum levels, n (%) | |
< 30 UI/mL | 2 (1.6) |
≥ 30 UI/mL | 118 (98.4) |
Prick test result, n (%) | |
Positive | 71 (84.5) |
Negative | 13 (15.4) |
Severe asthma classification criteria, n (%) | |
Steps 4 or 5 or use SC in more than 50% of the previous year | 116 (81.1) |
High doses of IC or SC to keep asthma under control | 27 (18.8) |
GINA assessment for asthma control, n (%) | |
Uncontrolled | 76 (76) |
Partly controlled | 16 (16) |
Well controlled | 8 (8) |
Deworming 12 months before t − 0, n (%) | |
Yes | 8 (5.6) |
No | 29 (20.3) |
No data | 106 (74.1) |